Memantine in Patients With Chronic Glaucoma

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00168350

Enrollment

1179

Registered

2005-09-15

Start date

2000-03-31

Completion date

2006-09-30

Last updated

2010-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-Angle Glaucoma

Brief summary

Randomized double-masked clinical trial of memantine in patients with glaucoma

Interventions

DRUGmemantine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 82 Years

Healthy volunteers

Inclusion criteria

* glaucoma damage on examination of visual field and optic disc * good visual acuity (with glasses if needed)

Design outcomes

Primary

Measure	Time frame
Progression of glaucoma	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026